JP2019501204A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501204A5
JP2019501204A5 JP2018536116A JP2018536116A JP2019501204A5 JP 2019501204 A5 JP2019501204 A5 JP 2019501204A5 JP 2018536116 A JP2018536116 A JP 2018536116A JP 2018536116 A JP2018536116 A JP 2018536116A JP 2019501204 A5 JP2019501204 A5 JP 2019501204A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018536116A
Other languages
English (en)
Japanese (ja)
Other versions
JP6867395B2 (ja
JP2019501204A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013066 external-priority patent/WO2017123669A1/en
Publication of JP2019501204A publication Critical patent/JP2019501204A/ja
Publication of JP2019501204A5 publication Critical patent/JP2019501204A5/ja
Application granted granted Critical
Publication of JP6867395B2 publication Critical patent/JP6867395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018536116A 2016-01-11 2017-01-11 Sting活性と関連のある症状、例えば癌を治療するための環状ジヌクレオチド Active JP6867395B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277273P 2016-01-11 2016-01-11
US62/277,273 2016-01-11
US201662436759P 2016-12-20 2016-12-20
US62/436,759 2016-12-20
PCT/US2017/013066 WO2017123669A1 (en) 2016-01-11 2017-01-11 Cyclic dinucleotides for treating conditions associated with sting activity such as cancer

Publications (3)

Publication Number Publication Date
JP2019501204A JP2019501204A (ja) 2019-01-17
JP2019501204A5 true JP2019501204A5 (enExample) 2020-02-06
JP6867395B2 JP6867395B2 (ja) 2021-04-28

Family

ID=58010371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536116A Active JP6867395B2 (ja) 2016-01-11 2017-01-11 Sting活性と関連のある症状、例えば癌を治療するための環状ジヌクレオチド

Country Status (27)

Country Link
US (3) US10604542B2 (enExample)
EP (1) EP3402801B1 (enExample)
JP (1) JP6867395B2 (enExample)
KR (2) KR20250049441A (enExample)
CN (1) CN109451740B (enExample)
AU (1) AU2017207757B2 (enExample)
BR (1) BR112018013808A2 (enExample)
CA (1) CA3011528A1 (enExample)
CL (1) CL2018001870A1 (enExample)
CO (1) CO2018008196A2 (enExample)
DK (1) DK3402801T3 (enExample)
EA (1) EA036421B1 (enExample)
ES (1) ES3046957T3 (enExample)
FI (1) FI3402801T3 (enExample)
HR (1) HRP20251050T1 (enExample)
IL (1) IL260427B (enExample)
LT (1) LT3402801T (enExample)
MX (1) MX2018008266A (enExample)
MY (1) MY194058A (enExample)
PE (1) PE20181330A1 (enExample)
PL (1) PL3402801T3 (enExample)
PT (1) PT3402801T (enExample)
RS (1) RS67188B1 (enExample)
SG (1) SG11201805888SA (enExample)
SI (1) SI3402801T1 (enExample)
SM (1) SMT202500412T1 (enExample)
WO (1) WO2017123669A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
PT3402801T (pt) * 2016-01-11 2025-10-23 Innate Tumor Immunity Inc Dinucleótidos cíclicos para o tratamento de condições associadas à atividade de sting, tal como cancro
HUE060396T2 (hu) 2016-03-18 2023-02-28 Immune Sensor Llc Ciklikus DI-nukleotid vegyületek és azok felhasználási módszerei
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
JP7100227B2 (ja) 2016-07-06 2022-07-13 エフ-スター・セラピューティクス・インコーポレイテッド 疾患の治療のための化合物、組成物、および方法
EP3922279B8 (en) 2016-08-30 2025-02-12 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
RS62410B1 (sr) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]tiofenska jedinjenja kao agonisti sting
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
TW202430219A (zh) 2017-04-13 2024-08-01 荷蘭商賽羅帕公司 抗-SIRPα 抗體
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US11259980B2 (en) 2017-07-31 2022-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Soft inflatable exosuit for knee rehabilitation
MA49773A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
CA3071538A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
AU2018323053A1 (en) 2017-08-30 2020-03-19 Beijing Xuanyi Pharmasciences Co., Ltd Cyclic di-nucleotides as stimulator of interferon genes modulators
EP3676277A1 (en) * 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
EA202090719A1 (ru) 2017-09-14 2020-07-01 Янссен Байофарма, Инк. Модифицированные нуклеозидные амидофосфиты
WO2019074887A1 (en) * 2017-10-10 2019-04-18 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
EP3505527A1 (en) * 2017-12-29 2019-07-03 Invivogen Cyclic dinucleotides for cytokine induction
US10519187B2 (en) * 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7250808B2 (ja) * 2018-03-08 2023-04-03 ブリストル-マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
WO2019180683A1 (en) 2018-03-23 2019-09-26 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
EP3774764A1 (en) 2018-04-03 2021-02-17 Merck Sharp&Dohme Corp. Benzothiophenes and related compounds as sting agonists
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
MA52754A (fr) 2018-05-25 2021-04-14 Incyte Corp Composés hétérocycliques tricycliques en tant qu'activateurs de sting
WO2020014127A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為sting促效劑之環狀二核苷酸
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
CA3099904A1 (en) 2018-08-16 2020-02-20 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
PT3848054T (pt) 2018-09-06 2025-04-03 Daiichi Sankyo Co Ltd Conjugados anticorpo-fármaco de derivados de dinucleótidos cíclicos
KR20210081332A (ko) 2018-09-12 2021-07-01 실버백 테라퓨틱스, 인크. 면역 자극성 접합체를 사용한 질환의 치료를 위한 조성물
BR112021005208A2 (pt) 2018-09-21 2021-06-08 Shanghai De Novo Pharmatech Co., Ltd. análogo de dinucleotídeo cíclico, composição farmacêutica do mesmo, e aplicação
WO2020092127A1 (en) 2018-10-29 2020-05-07 Venenum Biodesign, LLC Novel sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
MX2021006498A (es) * 2018-12-04 2021-07-06 Bristol Myers Squibb Co Proceso para la preparacion de un dinucleotido ciclico.
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CN113423713A (zh) * 2019-02-05 2021-09-21 百时美施贵宝公司 1,2,5-三-o-苯甲酰基-3-二苄基氨基-3-脱氧核糖作为生产3′-氨基-3′-脱氧腺苷和3′-氨基-3′-脱氧鸟苷的中间体及其受保护的衍生物的合成
CN114173824A (zh) 2019-05-10 2022-03-11 武田药品工业株式会社 抗体药物缀合物
CA3145889A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021013234A1 (en) * 2019-07-25 2021-01-28 Beigene, Ltd. Cyclic dinucleotides as sting agonists
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
JP7787514B2 (ja) 2019-12-26 2025-12-17 国立大学法人東海国立大学機構 ポリヌクレオチド及び医薬組成物
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン-4抗体コンジュゲートおよびその使用
KR20220151630A (ko) 2020-03-06 2022-11-15 다이이찌 산쿄 가부시키가이샤 신규 고리형 디뉴클레오티드 유도체를 포함하는 항체 약물 컨쥬게이트
JPWO2021206158A1 (enExample) 2020-04-10 2021-10-14
EP4138852A4 (en) * 2020-04-21 2024-05-15 Duke University COMPOSITIONS AND METHODS FOR TREATING PAIN
US20230226218A1 (en) 2020-05-11 2023-07-20 Erytech Pharma Red Cell Extracellular Vesicles (RCEVs) Containing Cargoes and Methods of Use and Production Thereof
CA3183993A1 (en) 2020-07-01 2022-01-06 Peter R. Baum Anti-asgr1 antibody conjugates and uses thereof
US20230256109A1 (en) 2020-08-07 2023-08-17 Tambo, Inc. Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy
WO2022050300A1 (ja) 2020-09-02 2022-03-10 第一三共株式会社 新規エンド-β-N-アセチルグルコサミニダーゼ
JP2023545466A (ja) * 2020-10-15 2023-10-30 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 免疫応答を調節することができる、金属イオンと会合したstingアゴニストの結晶多形体
KR102466750B1 (ko) * 2020-10-23 2022-11-15 아주대학교산학협력단 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
US20230390409A1 (en) 2020-10-30 2023-12-07 Avacta Life Sciences Limited Fap-activated serum extended half-life therapeutic conjugates
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
WO2023277168A1 (ja) 2021-06-30 2023-01-05 協和キリン株式会社 ポリヌクレオチド及び医薬組成物
IL315341A (en) 2022-03-02 2024-10-01 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
EP4582106A1 (en) 2022-08-29 2025-07-09 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
BR0312442A (pt) 2002-06-20 2005-05-10 Nippon Suisan Kaisha Ltd Pró-droga, utilização medicinal desta e processo para produzir a mesma
JP4931798B2 (ja) * 2004-03-15 2012-05-16 ケイ.アール. カラオリス,デイヴィッド 免疫、炎症または神経保護応答のための方法
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
WO2014093936A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
MX374828B (es) 2013-04-29 2025-03-06 Memorial Sloan Kettering Cancer Center Composiciones y metodos para alterar la señalizacion del segundo mensajero.
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
HK1223794A1 (zh) 2013-10-21 2017-08-11 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
US20160287623A1 (en) 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment
US20150144176A1 (en) 2013-11-22 2015-05-28 Massachusetts Institute Of Technology Photovoltaic power balancing and differential power processing
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
US10450341B2 (en) 2014-06-04 2019-10-22 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
PL3233882T3 (pl) 2014-12-16 2020-04-30 Kayla Therapeutics Fluorowane cykliczne dinukleotydy do indukcji cytokin
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
PT3402801T (pt) * 2016-01-11 2025-10-23 Innate Tumor Immunity Inc Dinucleótidos cíclicos para o tratamento de condições associadas à atividade de sting, tal como cancro
HUE060396T2 (hu) 2016-03-18 2023-02-28 Immune Sensor Llc Ciklikus DI-nukleotid vegyületek és azok felhasználási módszerei

Similar Documents

Publication Publication Date Title
JP2019501204A5 (enExample)
JP2015534577A5 (enExample)
TWI786044B (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
JP2016520082A5 (enExample)
JP2016502504A5 (enExample)
JP2020536971A5 (enExample)
JP2018508512A5 (enExample)
JP2015534580A5 (enExample)
RU2015149285A (ru) Схемы дозирования иммуноконъюгата anti-folr1
JP2019506403A5 (enExample)
JP2014034576A5 (enExample)
JP2018516966A5 (enExample)
JP2018504418A5 (enExample)
JP2017533912A5 (enExample)
JP2015534579A5 (enExample)
JP2018516969A5 (enExample)
WO2016204193A1 (ja) 抗がん剤
JP2016528246A5 (enExample)
JP2020506951A5 (enExample)
JP2015512398A5 (enExample)
JP2017510661A5 (enExample)
JP2012158602A5 (enExample)
JP2018537975A5 (enExample)
JP2020532542A5 (enExample)
JP2020536897A5 (enExample)